Remedy Plan Therapeutics Announces Multiple Development and Corporate Milestones as First-In-Class Hyperbolic NAMPT Inhibitor, RPT1G, Advances in Phase 1 Dose Escalation Trial in AML/MDS

Phase 1RPT1GPositive

AI Analysis

Summary

Remedy Plan Therapeutics announced advancement of RPT1G, a first-in-class hyperbolic NAMPT inhibitor, into Cohort 2 of a Phase 1 dose escalation trial in relapsed/refractory AML and higher-risk MDS.

Clinical Trial Data

Phase

Importance:5/10

Sentiment:

0.50

Phase 1AMLMDSNAMPT inhibitordose escalationfirst-in-class

Related Companies

$INTI $TRAX

Read the original article

Published by GlobeNewswire Clinical Studies on September 15, 2026 11:00 AM

Read Original